- Corporate Officers - R
- Riedel Norbert G
Insider Trading History of Riedel Norbert G
The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Riedel Norbert G since 2007.
This trader's CIK number is 1161662.
At the time of last reporting, Riedel Norbert G was the Director of Eton Pharmaceuticals, Inc.. (stock ticker symbol ETON).
Also see all insider trading activities at Eton Pharmaceuticals, Inc..
Note that in the past
RIEDEL NORBERT G also reported insider trading activities as an insider of the following companies:
Yearly summary of insider trading at Cerevel Therapeutics Holdings, Inc. (CERE) by Riedel Norbert G
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2022 | CERE | 0 | $0 | 0 | $0 | 14,270 | $0 |
| 2021 | CERE | 0 | $0 | 0 | $0 | 14,270 | $0 |
Yearly summary of insider trading at Aptinyx Inc. (APTX) by Riedel Norbert G
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2021 | APTX | 100,000 | $223,000 | 0 | $0 | 380,000 | $0 |
| 2020 | APTX | 35,000 | $105,000 | 0 | $0 | 0 | $0 |
| 2018 | APTX | 2,400 | $38,400 | 0 | $0 | 38,563 | $99,878 |
Yearly summary of insider trading at Baxter International Inc (BAX) by Riedel Norbert G
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2012 | BAX | 0 | $0 | 70,125 | $4,136,673 | 70,125 | $2,689,293 |
| 2010 | BAX | 0 | $0 | 75,600 | $4,482,324 | 75,600 | $3,745,224 |
| 2009 | BAX | 0 | $0 | 194,800 | $11,113,200 | 194,800 | $7,095,657 |
| 2007 | BAX | 0 | $0 | 94,284 | $5,419,325 | 94,284 | $2,814,006 |
Yearly summary of insider trading at Jazz Pharmaceuticals Plc (JAZZ) by Riedel Norbert G
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2023 | JAZZ | 0 | $0 | 1,241 | $171,454 | 0 | $0 |
| 2022 | JAZZ | 0 | $0 | 9,089 | $1,412,796 | 8,000 | $442,240 |
| 2021 | JAZZ | 0 | $0 | 1,306 | $193,235 | 0 | $0 |
| 2020 | JAZZ | 0 | $0 | 931 | $117,185 | 0 | $0 |
| 2019 | JAZZ | 0 | $0 | 726 | $98,481 | 0 | $0 |
| 2018 | JAZZ | 0 | $0 | 660 | $116,563 | 0 | $0 |
| 2017 | JAZZ | 0 | $0 | 662 | $94,828 | 0 | $0 |
| 2016 | JAZZ | 0 | $0 | 1,277 | $179,880 | 0 | $0 |
| 2015 | JAZZ | 0 | $0 | 1,451 | $258,925 | 0 | $0 |
| 2014 | JAZZ | 0 | $0 | 644 | $91,763 | 0 | $0 |
Yearly summary of insider trading at Eton Pharmaceuticals, Inc. (ETON) by Riedel Norbert G
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2025 | ETON | 0 | $0 | 0 | $0 | 102,400 | $369,664 |
| 2018 | ETON | 5,000 | $30,000 | 0 | $0 | 0 | $0 |
Insider trading activities at 5 companies by Riedel Norbert G:
1. Cerevel Therapeutics Holdings, Inc. (CERE)
2. Aptinyx Inc. (APTX)
3. Baxter International Inc (BAX)
4. Jazz Pharmaceuticals Plc (JAZZ)
5. Eton Pharmaceuticals, Inc. (ETON)
Table 1. Insider trading of Cerevel Therapeutics Holdings, Inc. (CERE) by Riedel Norbert G
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2022-01-04 | CERE | Option Ex | 14,270 | .00 | 0 |
| 2021-01-04 | CERE | Option Ex | 14,270 | .00 | 0 |
Table 2. Insider trading of Aptinyx Inc. (APTX) by Riedel Norbert G
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2021-12-06 | APTX | Buy | 100,000 | 2.23 | 223,000 |
| 2021-05-17 | APTX | Option Ex | 380,000 | .00 | 0 |
| 2020-01-10 | APTX | Buy | 35,000 | 3.00 | 105,000 |
| 2018-11-12 | APTX | Option Ex | 38,563 | 2.59 | 99,878 |
| 2018-06-25 | APTX | Buy | 2,400 | 16.00 | 38,400 |
Table 3. Insider trading of Baxter International Inc (BAX) by Riedel Norbert G
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2012-08-03 | BAX | Option Ex | 70,125 | 38.35 | 2,689,293 |
| 2012-08-03 | BAX | Sale | 70,125 | 58.99 | 4,136,673 |
| 2010-03-05 | BAX | Option Ex | 75,600 | 49.54 | 3,745,224 |
| 2010-03-05 | BAX | Sale | 75,600 | 59.29 | 4,482,324 |
| 2009-12-02 | BAX | Sale | 92,500 | 55.92 | 5,172,600 |
| 2009-12-02 | BAX | Option Ex | 92,500 | 30.99 | 2,866,575 |
| 2009-01-26 | BAX | Option Ex | 22,300 | 41.34 | 921,882 |
| 2009-01-27 | BAX | Option Ex | 80,000 | 41.34 | 3,307,200 |
| 2009-01-26 | BAX | Sale | 22,300 | 58.00 | 1,293,400 |
| 2009-01-27 | BAX | Sale | 80,000 | 58.09 | 4,647,200 |
| 2007-06-05 | BAX | Option Ex | 54,584 | 30.76 | 1,678,785 |
| 2007-06-06 | BAX | Option Ex | 39,700 | 28.59 | 1,135,221 |
| 2007-06-05 | BAX | Sale | 54,584 | 57.54 | 3,140,545 |
| 2007-06-06 | BAX | Sale | 39,700 | 57.40 | 2,278,780 |
Table 4. Insider trading of Jazz Pharmaceuticals Plc (JAZZ) by Riedel Norbert G
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2023-08-14 | JAZZ | Sale | 1,241 | 138.16 | 171,454 |
| 2022-08-05 | JAZZ | Option Ex | 8,000 | 55.28 | 442,240 |
| 2022-08-05 | JAZZ | Sale | 8,000 | 155.87 | 1,246,920 |
| 2022-08-08 | JAZZ | Sale | 1,089 | 152.32 | 165,876 |
| 2021-08-06 | JAZZ | Sale | 1,306 | 147.96 | 193,235 |
| 2020-08-07 | JAZZ | Sale | 931 | 125.87 | 117,185 |
| 2019-08-09 | JAZZ | Sale | 726 | 135.65 | 98,481 |
| 2018-08-10 | JAZZ | Sale | 660 | 176.61 | 116,563 |
| 2017-08-11 | JAZZ | Sale | 662 | 143.25 | 94,828 |
| 2016-08-15 | JAZZ | Sale | 633 | 136.45 | 86,372 |
| 2016-05-16 | JAZZ | Sale | 644 | 145.20 | 93,508 |
| 2015-08-10 | JAZZ | Sale | 801 | 181.67 | 145,517 |
| 2015-05-12 | JAZZ | Sale | 650 | 174.47 | 113,408 |
| 2014-05-28 | JAZZ | Sale | 644 | 142.49 | 91,763 |
Table 5. Insider trading of Eton Pharmaceuticals, Inc. (ETON) by Riedel Norbert G
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2025-01-03 | ETON | Option Ex | 102,400 | 3.61 | 369,664 |
| 2018-11-15 | ETON | Buy | 5,000 | 6.00 | 30,000 |
Insider trading activities including stock purchases, stock sales, and option exercises
listed in the above table cannot be completely guaranteed as to their accuracy.
For more information regarding the trades made by Riedel Norbert G
(Director of Eton Pharmaceuticals, Inc. at the time of this reporting) see
the Securities and Exchange Commission (SEC) website.